1. Home
  2. XWIN vs NGNE Comparison

XWIN vs NGNE Comparison

Compare XWIN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XWIN

XMAX Inc.

N/A

Current Price

$8.38

Market Cap

353.6M

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$31.00

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XWIN
NGNE
Founded
2003
2003
Country
United States
United States
Employees
22
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.6M
327.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
XWIN
NGNE
Price
$8.38
$31.00
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$63.57
AVG Volume (30 Days)
986.7K
165.1K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.20
$13.93
52 Week High
$8.27
$37.27

Technical Indicators

Market Signals
Indicator
XWIN
NGNE
Relative Strength Index (RSI) 85.44 68.67
Support Level $5.58 $19.40
Resistance Level N/A $32.02
Average True Range (ATR) 0.21 2.05
MACD 0.06 0.36
Stochastic Oscillator 95.88 70.75

Price Performance

Historical Comparison
XWIN
NGNE

About XWIN XMAX Inc.

XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: